MarketCap
Facebook
X
TelegramQuarterly report 2024-Q4
added 01-10-2025
Accolade General and Administrative Expenses 2011-2026 | ACCD
General and Administrative Expenses — these are a part of a company's operating expenses that are not directly related to the production of goods or the provision of services but are necessary for the overall functioning of the business.What these expenses include
- Salaries of administrative staff (executives, HR, accountants, legal personnel)
- Office rent and utilities
- Office equipment and IT infrastructure
- Professional services (auditors, lawyers, consultants)
- Insurance
- General administrative travel and representation expenses
- Cost control
A high level of such expenses may indicate inefficient management or an overly complex structure - Profitability
Reducing administrative expenses while maintaining stable revenue increases operating profit - Comparative analysis
Investors can compare this metric as a percentage of revenue among companies in the same industry - Business flexibility
Companies with a flexible and controlled expense structure are more resilient to revenue declines
Annual General and Administrative Expenses Accolade
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 31.6 M | 26.2 M | 19.7 M | 21.1 M | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 31.6 M | 19.7 M | 24.6 M |
Quarterly General and Administrative Expenses Accolade
| 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 16.2 M | 16.5 M | 16 M | - | 15.5 M | 16.3 M | 16.1 M | - | 20 M | 21 M | 20.2 M | - | 21.5 M | 69.6 M | 48.2 M | 22 M | 8.41 M | 8.41 M | 6.45 M | 5.67 M | 8.55 M | 6.01 M | 5.56 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 69.6 M | 5.56 M | 18.4 M |
General and Administrative Expenses of other stocks in the Health information services industry
| Issuer | General and Administrative Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Cerner Corporation
CERN
|
521 M | - | - | $ 27.9 B |  USA |
 |
Change Healthcare
CHNG
|
687 M | - | - | $ 9.03 B | USA |
 |
Computer Programs and Systems
CPSI
|
76.2 M | - | 4.4 % | $ 133 M | USA |
 |
Covetrus
CVET
|
881 M | - | - | $ 2.94 B | USA |
 |
Castlight Health, Inc.
CSLT
|
25.7 M | - | -7.28 % | $ 227 M | USA |
 |
HMS Holdings Corp.
HMSY
|
123 M | - | - | $ 3.29 B | USA |
 |
Inovalon Holdings, Inc.
INOV
|
217 M | - | - | $ 6.37 B | USA |
 |
Evolent Health
EVH
|
269 M | $ 4.1 | 1.99 % | $ 384 M | USA |
 |
Health Catalyst
HCAT
|
56.8 M | $ 2.48 | 3.99 % | $ 149 M | USA |
 |
iCAD
ICAD
|
7.63 M | - | - | $ 102 M | USA |
 |
HealthStream
HSTM
|
35.1 M | $ 22.67 | -2.07 % | $ 689 M | USA |
 |
Akerna Corp.
KERN
|
11.3 M | - | - | $ 161 M | USA |
 |
HealthEquity
HQY
|
104 M | $ 97.34 | 1.97 % | $ 8.33 B | USA |
 |
American Well Corporation
AMWL
|
121 M | $ 5.11 | -4.49 % | $ 76.6 M | USA |
 |
Allscripts Healthcare Solutions
MDRX
|
314 M | - | -10.39 % | $ 886 M | USA |
 |
MTBC
MTBC
|
16.1 M | - | -0.58 % | $ 51.7 M | USA |
 |
GoodRx Holdings
GDRX
|
118 M | $ 2.89 | -0.34 % | $ 1.11 B | USA |
 |
OptimizeRx Corporation
OPRX
|
776 K | $ 13.88 | 4.2 % | $ 238 M | USA |
 |
Omnicell
OMCL
|
380 M | $ 47.55 | 1.02 % | $ 2.19 B | USA |
 |
1Life Healthcare
ONEM
|
323 M | - | - | $ 3.37 B | USA |
 |
So-Young International
SY
|
252 M | $ 2.55 | -3.6 % | $ 202 M |  China |
 |
Progyny
PGNY
|
32 M | $ 26.68 | 0.04 % | $ 2.29 B | USA |
 |
Phreesia
PHR
|
79.9 M | $ 17.53 | 1.8 % | $ 956 M | USA |
 |
Premier
PINC
|
701 M | $ 28.26 | - | $ 2.33 B | USA |
 |
R1 RCM
RCM
|
120 M | - | - | $ 3.81 B | USA |
 |
Veeva Systems
VEEV
|
247 M | $ 239.12 | 0.45 % | $ 38.4 B | USA |
 |
NantHealth
NH
|
62.5 M | - | -46.64 % | $ 10.4 M | USA |
 |
Zhongchao
ZCMD
|
4.99 M | $ 0.5 | -4.6 % | $ 2.6 M | China |
 |
NextGen Healthcare
NXGN
|
181 M | - | - | $ 1.6 B | USA |
 |
Schrödinger
SDGR
|
99.7 M | $ 18.77 | 0.03 % | $ 1.36 B | USA |
 |
Signify Health
SGFY
|
202 M | - | -0.02 % | $ 7.21 B | USA |
 |
Streamline Health Solutions
STRM
|
11.7 M | - | - | $ 21.4 M | USA |
 |
10x Genomics
TXG
|
343 M | $ 19.88 | 2.93 % | $ 2.33 B | USA |
 |
Teladoc Health
TDOC
|
435 M | $ 7.6 | -5.06 % | $ 1.3 B | USA |
 |
Tabula Rasa HealthCare
TRHC
|
75 M | - | - | $ 255 M | USA |
 |
SCWorx Corp.
WORX
|
765 K | $ 0.2 | -3.49 % | $ 292 K | USA |